Clinical Trials
180
17 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1828
Active, not recruiting
9
5.0%
Available
1
0.6%
Completed
85
47.2%
Enrolling By Invitation
1
0.6%
Not yet recruiting
7
3.9%
Recruiting
22
12.2%
Terminated
13
7.2%
Unknown
37
20.6%
Withdrawn
5
2.8%
No approval data available
- Researchers at Augusta University discovered that combining beta-blockers with oncolytic herpes simplex virus significantly improves breast cancer treatment by blocking tumor's protective mechanisms and reprogramming immune cells. - Scientists at The Institute of Cancer Research demonstrated that pairing reovirus with targeted drugs talazoparib and palbociclib dramatically boosts immune responses and cancer cell death in laboratory and mouse studies. - Both studies reveal how tumors manipulate the body's stress responses and immune systems to resist treatment, offering new strategies for more effective personalized cancer therapies. - The combination approaches not only enhance immediate tumor destruction but also help train the immune system to develop memory against cancer recurrence.
- A randomized controlled trial reveals vitamin D supplementation helps maintain telomeres, protective chromosome caps that shorten during aging, effectively preventing nearly three years of biological aging. - The VITAL trial, the first large-scale long-term study of its kind, demonstrated that daily vitamin D3 (2,000 IU) significantly reduced telomere shortening over four years compared to placebo. - Researchers note these findings align with previous VITAL results showing vitamin D benefits in reducing inflammation and lowering risks of advanced cancer and autoimmune disease.
- A recent study identifies early improvements in specific depressive symptoms as predictors of response to repetitive transcranial magnetic stimulation (rTMS). - Patients showing early improvement in initiative and emotional involvement are more likely to respond positively to rTMS treatment. - Longer depressive episode duration and a history of electroconvulsive therapy (ECT) are associated with lower odds of rTMS response. - The findings suggest that monitoring early symptom changes can help predict rTMS efficacy and personalize treatment strategies.
